tbuckley/cabot-search huggingface dataset:
Immune Responses in Farm Workers after Exposure to Bacillus thuringiensis Pesticides
Authors: I. Leonard Bernstein, Jonathan A. Bernstein, Maureen Miller, Sylva Tierzieva, David I. Bernstein, Zana Lummus, MaryJane K. Selgrade, Donald L. Doerfler, Verner L. Seligy
Journal: Environmental Health Perspectives (1999)

Although health risks to pesticides containing Bacillus thuringiensis (Bt) have been minimal, the potential allergenicity of these organisms has not been evaluated. Therefore, a health survey was conducted in farm workers before and after exposure to Bt pesticides. Farm workers who picked vegetables that required Bt pesticide spraying were evaluated before the initial spraying operation (n = 48) and 1 and 4 months after (n = 32 and 20, respectively). Two groups of low- (n = 44) and medium- (n = 34) exposure workers not directly exposed to Bt spraying were also assessed. The investigation included questionnaires, nasal/mouth lavages, ventilatory function assessment, and skin tests to indigenous aeroallergens and to a variety of Bt spore and vegetative preparations. To authenticate exposure to the organism present in the commercial preparation, isolates from lavage specimens were tested for Bt genes by DNA-DNA hybridization. Humoral immunoglobulin G (IgG) and immunoglobulin E (IgE) antibody responses to spore and vegetative Bt extracts were assayed. There was no evidence of occupationally related respiratory symptoms. Positive skin-prick tests to several spore extracts were seen chiefly in exposed workers. In particular, there was a significant (p < 0.05) increase in the number of positive skin tests to spore extracts 1 and 4 months after exposure to Bt spray. The number of positive skin test responses was also significantly higher in high (p < 0.05) than in low- or medium-exposure workers. The majority of nasal lavage cultures from exposed workers was positive for the commercial Bt organism, as demonstrated by specific molecular genetic probes. Specific IgE antibodies were present in more high-exposure workers (p < 0.05) than in the low and medium groups. Specific IgG antibodies occurred more in the high (p < 0.05) than in the low-exposure group. Specific IgG and IgE antibodies to vegetative organisms were present in all groups of workers. Exposure to Bt sprays may lead to allergic skin sensitization and induction of IgE and IgG antibodies, or both.
PORTRAIT OF HARVEY AS A YOUNG MAN
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AIRBORNE TYPHOID
Authors: R. H. Quill
Journal: BMJ (1902)

authority.Who can as yet control the atmosphere?The wind bloweth where it listeth.In conclusion I hope, by a simple device in a year or so, to be able to contrast the frequency of typhoid with the comparative prevalence of flies, and also with the average amount of dust blown through a given vertical area.I am collecting evidence on the subject of typhoid fever and the variations in the condition of the water supply, but as yet it is too soon to publish the results I have obtained.
THE PRESIDENT'S ADDRESS, AND THE ANNUAL ORATIONS.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ETHYLENE—II
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
July 1981, vol 67, No. 1
Journal: JNCI Journal of the National Cancer Institute (1981)

July 1981, vol 67, No. 1 Get access JNCI: Journal of the National Cancer Institute, Volume 67, Issue 3, September 1981, Page 741, https://doi.org/10.1093/jnci/67.3.741-a Published: 01 September 1981
DISEASE AND MUNICIPAL RESPONSIBILITY.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hantavirus Pulmonary Syndrome— Northeastern United States, 1994
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation
Authors: D Gallardo, R De la Cámara, A Torres, S Brunet, A Jiménez, J C Vallejo, G Sanz, D Serrano, E Carreras, C Martín, C Sanz-Rodríguez, J Sierra, I Espigado, D Caballero, J J Berlanga
Journal: Leukemia (2004)
Research—A National Resource. II.—Industrial Research. December 1940
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tuberculous meningitis
Authors: D. H. Kennedy
Journal: JAMA (1979)

To evaluate modern treatment and identify important factors influencing the outcome of tuberculous meningitis, clinical and laboratory findings in 52 patients aged from 9 months to 68 years have been reviewed. Patients were classified by clinical criterions at admission and at the start of treatment. Delay in commencing treatment was associated with deterioration and consequently poorer prognosis, but some severely ill patients made a good recovery. Forty-four survivors (85%) recovered, and only two patients (4%) had severe residual disability; eight (15%) of the patients died. Treatment should commence as soon as possible on clinical grounds without necessarily waiting for demonstration of<i>Mycobacterium tuberculosis</i>, as the organism can often be demonstrated in CSF withdrawn after the start of drug therapy. (<i>JAMA</i>241:264-268, 1979)
Significance of zoledronic acid on survival in patients with bone metastases from renal cell carcinoma.
Authors: Yosuke Yasuda, Yasuhisa Fujii, Takeshi Yuasa, Shinichi Kitsukawa, Shinji Urakami, Shinya Yamamoto, Junji Yonese, Shunji Takahashi, Iwao Fukui
Journal: Journal of Clinical Oncology (2013)

374 Background: It remains unclear whether zoledronic acid (ZOL) improves overall survival (OS) for renal cell carcinoma (RCC) patients with bone metastases. We retrospectively investigated the clinical benefit of ZOL for OS in RCC patients with bone metastases. Methods: Between 1978 and 2010, 77 patients who had RCC metastatic to bone were treated in our hospital. Of them, 36 were treated with ZOL and their OS was significantly better than that of the other 41 patients (1- and 3-year survival, 84% and 73% vs. 49% and 27%, respectively, p &lt; 0.001). OS rates were clearly discriminated according to MSKCC model stratification: 3-year survival rates in the favorable, intermediate and poor risk groups were 83% (n = 12), 49% (n = 45), and 19% (n = 20), respectively (p=0.0033). To match characteristics in our retrospective study, we selected 45 patients conforming to MSKCC intermediate risk group criterion. In this cohort, 23 patients received ZOL (ZOL-treated group) whereas the other 22 did not (non-ZOL-treated group). The primary endpoint was OS and the secondary endpoint was the skeletal-related event (SRE) rate defined as the total number of SREs divided by the total years on study. Results: For the cohort of 45 patients, the median OS from diagnosis of bone metastases was 27.2 months. Multivariate analysis showed that low serum calcium (hazard ratio [HR]: 2.58, 95% confidence interval [CI]: 1.31 to 4.69; p = 0.0083) and ZOL treatment (HR: 1.89, 95% CI: 1.27 to 2.96; p = 0.0013) were independent factors predicting longer survival. The ZOL-treated group had significantly longer OS (1-year survival: 80.8%) than the non-ZOL-treated group (1-year survival: 59.1%, p = 0.0034). A difference in OS between the two groups still was present (p = 0.012) when the duration of molecular-targeted therapy was excluded from the OS period. Patients in the ZOL-treated group experienced a lower SRE rate (0.87/year) than patients in the non-ZOL-treated group (1.82/year, p = 0.0453). In particular, none of the patients in the ZOL-treated group developed spinal compression whereas 6 (28%) in the non-ZOL-treated group did (p = 0.0479). Conclusions: The current study indicates that ZOL not only reduces SREs but possibly improves OS in these patients.
Familial Schmidt's syndrome
Authors: P. B. Anderson
Journal: JAMA (1980)

Among the 17 offspring of a common father, overt adrenal and thyroid insufficiency developed in three brothers. In eight of the 12 siblings then examined, and also in one of the two mothers of this kindred, endocrine abnormalities were documented. Early compensated adrenal and thyroid hypofunction with organ-specific antibodies were found in asymptomatic relatives. Pernicious anemia, vitiligo, and alopecia were also seen. Age of clinical onset varied from 18 to 38 years. Familial investigations may identify asymptomatic persons at risk for the development of serious endocrine deficiencies. (<i>JAMA</i>244:2068-2070, 1980)
Statement on heart transplantation
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Carcinoma of the breast. Stage II--radiation range. Can survival be increased by postoperative irradiation following radical mastectomy?
Authors: T. A. Watson
Journal: JAMA (1967)

The operation of radical mastectomy is widely, and in my opinion, properly employed in the management of patients with stage II cancer of the breast. If the axillary nodes are found to be negative on microscopic examination, and if the primary tumor is small and confined to the outer aspect of the breast, the most common site, then radiotherapy is not indicated. If, however, the primary tumor is situated in the inner aspect of the breast or centrally or if the tumor is large or the axillary nodes are found by the pathologist to contain metastases, then the question immediately arises as to whether the tumor has already spread beyond the limits of the operation. If such is the case then it would seem logical to supplement surgery by some form of treatment which has a chance of being curative. Undoubtedly the most important therapeutic measure in moderately advanced carcinoma
MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data
Authors: P. Squiban, T. Velu, B. Mennecier, M. Pless, V. Morel, E. Levy, V. Richard, T. Maciejewska, N. Bizouarne, E. Quoix
Journal: Journal of Clinical Oncology (2004)

2544 Background: Over-expression, non-polarity and under-glycosylation of the mucin glycoprotein molecule, MUC1, are associated with many cancers, making MUC1 an attractive target antigen for vaccine immunotherapy of cancer. MVA (Modified Vaccinia Ankara), a highly attenuated Vaccinia virus, is non-propagative in most mammalian cells and has an excellent safety profile. We have produced a recombinant MVA expressing MUC1 and IL2 (TG4010). Murine studies have shown that TG4010 can induce a MUC1 specific immune response associated with the elimination of MUC1 expressing tumors. In a Phase I study of TG4010 in patients with late stage, MUC1 expressing cancers, TG4010 was well tolerated and showed some evidence of efficacy. We have initiated a Phase II study in which TG4010 is assessed alone or in combination with chemotherapy in NSCLC patients. Methods: A randomized, two stage Simon design, two arm (18 / 33 patients stage 1 / 2 per arm ), phase II study in stage IIIb / IV NSCLC is described . Arm 1: TG4010 is combined upfront with cisplatin and vinorelbine. Arm 2: patients are treated with TG4010 alone, followed by TG4010 + cisplatin and vinorelbine upon disease progression. Results: A this time 45 patients (9 stage IIIb- 36 stage IV) have been enrolled. In arm 1, interim data show an objective response rate (ORR) of 5 / 12 patients so far validated by independent central review (response duration 114–195 days). ORR already satisfies the criteria to move forward to the second stage of the study. In Arm 2, disease control is observed in 4 / 15 patients with TG4010 alone, and to date, an ORR of 1 / 8 in subsequent combination with chemotherapy is observed. TG4010 is well tolerated. Injection site reaction is the most frequent adverse event. Conclusions: TG4010, combined with standard chemotherapy, is being evaluated further in stage 2 of the study. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Transgene Transgene Transgene
"A NEW CURE FOR INSANITY."
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New degree in international health starts in UK
Authors: R. MacDonald
Journal: BMJ (2001)

Drug companies neglect research into diseases affecting the poor 154, 254, 272, 217, Drugs companies are failing to develop new drugs for diseases that predominantly affect poor people because they are not profitable enough, says a report from the international medical aid agency Médecins Sans Frontières."Drugs are not developed according to public health need, but according to profitability," said Dr Bernard Pécoul, director of the agency's Campaign for Access to Essential Medicines.The report describes the research and development activities of 11 major pharmaceutical companies, representing combined sales of nearly $117bn (£78bn).The medical aid agency specifically asked them for the overall resources devoted to malaria, tuberculosis, sleeping sickness, Chagas' disease, and leishmaniasis.Eight of the 11 companies spent nothing in the last financial year on research and development on sleeping sickness, leishmaniasis, or Chagas' disease.One company did not answer the question.Two reported spending on malaria.Five reported spending on tuberculosis, but seven reported spending less than 1% of their research and development budget on any of the five diseases highlighted.Meanwhile a survey by the Pharmaceutical Research and Manufacturers of America showed that in 2000 there were eight drugs in development for impotence and erectile dysfunction, seven for obesity, and four for sleep disorders.
Long hours and risks to and from residents
Authors: Angelo P. Giardino
Journal: JAMA (1988)

<h3>To the Editor.</h3> —The recent letter by Drs Wendt and Yen<sup>1</sup>concerning house staff moonlighting seems to have missed the point entirely in the growing debate over residency training and safety to the patient and house staff officer. Drs Wendt and Yen report seven surgical residents who they informally surveyed concerning exhaustion and falling asleep at the wheel after a presumed 36- to 40-hour night on call. The article reported that six of the residents fell asleep at the wheel and that three were actually involved in motor vehicle accidents. From this information, the authors conclude that house staff should not moonlight. Is this the appropriate conclusion? A more reasoned approach to these disturbing statistics would be to evaluate why the residents were awake for such extended hours and what flaws in the training program are manifested in the expectation for residents to work long hours. Thus, if six
Anaphylaxis in Latin America: a Report of the Online Latin American Survey on Anaphylaxis (OLASA)
Authors: D. Sole, J. Ivancevich, M.S. Borges, M.A. Quadros-Coelho, N.A. Rosario, L. Ardusso, L.G. Bernd
Journal: Journal of Allergy and Clinical Immunology (2011)